InvestorsHub Logo
Followers 52
Posts 9089
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Monday, 11/06/2023 11:02:26 PM

Monday, November 06, 2023 11:02:26 PM

Post# of 13461
By the end of 2024, there's a good chance Spikevax won't be Moderna's only source of recurring revenue
Moderna expects an approval decision regarding its RSV vaccine candidate in April of 2024.

Moderna's RSV vaccine candidate, tentatively named mRNA-1354, reduced patients' risk of developing two or more RSV symptoms by 83.7% compared to a placebo. Moderna can argue that results for its candidate are best in class
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News